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Abstract
Bladder cancer is the fifth most frequent tumor in men and ninth in women in the United States. Due to a high
likelihood of recurrence, effective chemoprevention is a significant unmet need. Estrogen receptors (ERs), primarily
ERβ, are expressed in normal urothelium and urothelial carcinoma, and blocking ER function with selective ER
modulators such as tamoxifen inhibits bladder cancer cell proliferation in vitro. Herein, the chemoprotective potential
of tamoxifen was evaluated in female mice exposed to the bladder-specific carcinogen, N -butyl-N -(4-hydroxybutyl)
nitrosamine (BBN). Carcinogen treatment resulted in a 76% tumor incidence and increased mean bladder weights
in comparison to controls. In contrast, mice receiving tamoxifen concurrent (8–20 weeks) or concurrent and sub-
sequent (8–32 weeks) to BBN administration had no change in bladder weight and only 10% to 14% incidence of
tumors. Non–muscle-invasive disease was present in animals treated with tamoxifen before (5–8 weeks) or after
(20–32 weeks) BBN exposure, while incidence of muscle-invasive bladder carcinoma was reduced. ERβ was present
in all mice and thus is a potential mediator of the tamoxifen chemoprotective effect. Surprisingly, ERα expression,
which was detected in 74% of the mice exposed to BBN alone but not in any control mice, was correlated with tumor
incidence, indicating a possible role for this receptor in carcinogen-induced urothelial tumorigenesis. Thus, these data
argue that both ERα and ERβ play a role in modulating carcinogen-induced bladder tumorigenesis. Administration of
tamoxifen should be tested as a chemopreventive strategy for patients at high risk for bladder cancer recurrence.
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Introduction
As the fifth most common cancer in men and ninth most common
in women in the United States, urinary bladder cancer accounts for
significant morbidity and mortality. There are estimated to be more
than 73,000 new bladder cancer cases in 2012 [1] with urothelial
carcinoma accounting for approximately 90% of these; the remainder
is composed of squamous cell carcinomas, adenocarcinomas, and
other rare histologies [2]. Approximately 70% of all new bladder
cancer cases are classified as non–muscle-invasive (Ta, T1, Tis), while
the remaining 30% are muscle-invasive (T2–T4) and generally lead
to cystectomy. Bladder cancer recurs at a very high rate of 50% to
90% depending on the tumor stage, grade, and number of primary
tumors, and this necessitates lifetime monitoring for tumor recur-
rence. Therefore, there is a significant unmet need for approaches
to reduce the extent of urothelial cancer recurrence and, more impor-
tantly, to improve survival and maintain patient quality of life.
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There is a significant gender disparity in bladder cancer incidence
with three to four times more diagnoses in men than women [1].
Although environmental factors, such as cigarette smoking and in-
dustrial or occupational chemical exposure, which are greater in
men, contribute to this gender discrepancy, they do not fully account
for the excess risk in males [3]. This raises the possibility that intrin-
sic gender differences between males and females, such as the sex
steroid milieu, are a determinant of the relative preponderance of
bladder cancer in men. There is some rodent evidence suggesting
that androgens may promote bladder carcinogenesis [4,5], and andro-
gen receptors are present in human urothelial carcinomas [6–9].
Conversely, examining bladder cancer incidence relative to repro-
ductive events that alter exposure to estrogens and other reproductive
hormones suggests that estrogens may limit risk of urothelial carci-
noma in women. For instance, women who experience early meno-
pause are at higher risk [3], while parous women have a lower risk of
bladder cancer than nulliparous women [10–12]. In addition, use of
oral contraceptives and hormone replacement therapy also has been
associated with reduced bladder cancer risk [13,14]. Further support
for estrogens hindering urothelial carcinogenesis is found in adult
rodent models of bladder cancer, for both males and females [15,16].
Moreover, in a UPII-SV40T transgenic mouse model of bladder
cancer, tumors were significantly larger in nulliparous versus parous
animals [17]. Taken together, the cumulative evidence suggests that
female sex steroids may contribute to the lower risk of bladder cancer
in females than in males.
Estrogens mediate their pleiotropic and tissue-specific effects
through estrogen receptors (ERs), which bind this class of sex steroids
with high affinity and specificity. ERα (NR3A1) and ERβ (NR3A2)
belong to the nuclear receptor superfamily of transcription factors
that regulate various aspects of normal physiology including develop-
ment and function of the reproductive and other systems (e.g., skel-
etal and cardiovascular). In humans, early studies indicated ERα
expression in smooth muscle of the trigone and the posterior region
of the bladder neck [18,19]. More recently, approximately 50% of
the benign urothelium from analyses of 141 male and female patients
were positive for ERα with most showing weak expression [20]. In
contrast, a smaller study of 17 postmenopausal women indicated that
the bladder transitional epithelium was negative for ERα, while tran-
sitional epithelium of the urethra was positive [21]. Expression of
ERβ in the normal urothelium has also been evaluated in several
studies, and the preponderance of results indicates that this tissue
is largely positive for ERβ [20–23] with the exception of one report
that indicated that approximately one-third of the female specimens
was ERβ-positive, while this receptor was undetected in 58 male sam-
ples [8]. In rodents, there appears to be negligible ERα nuclear stain-
ing in the bladder [24,25], but ERβ is expressed in the urothelium
and smooth muscle in both sexes [26–31]. Thus, for both humans
and rodents, ERβ appears to be the predominant ER expressed in
normal urothelium.
In human bladder cancer, most reports indicate a low percentage
of tumors expressing ERα [32–36] with several studies failing to detect
any ERα expression [37,38]. A recent report indicated weak expression
of ERα in 27% of primary bladder cancer tissues, with no correlation
between ERα and tumor recurrence, progression, or cancer-specific
survival [20]. In contrast, strong ERβ is detected in human bladder
cancers in multiple studies, with up to 81% of tumors expressing this
form of ER [8,9,20,22,35,39,40]. Expression of ERβ appears to be
greater in high-grade versus low-grade tumors [20,35] and is associated
with recurrence and progression of low-grade tumors, recurrence of
muscle-invasive tumors, and reduced cancer-specific survival [20].
The greater expression of ERβ in urothelial carcinoma and its associa-
tion with poor outcome raises the possibility that blocking ERβ func-
tion may be beneficial with respect to inhibiting bladder tumorigenesis
and progression.
ERs can control proliferation, apoptosis, and migration/invasion
with the net biologic outcome depending on the relative expression
of ERα versus ERβ, as well as whether the regulating ligand is an estro-
gen or antiestrogen [41]. In some bladder cancer cell lines, estradiol can
induce DNA synthesis, suggestive of a growth stimulatory effect [42],
while in others this estrogen was unable to induce cell proliferation
[43]. In contrast, the antiestrogens raloxifene and tamoxifen inhibit
in vitro growth of multiple bladder cancer cell lines representative of
noninvasive and invasive tumors [35,43–45]. Moreover, tamoxifen
and raloxifene inhibited the growth of 5637 transitional cell carcinoma
xenografts in nude mice [44]. Collectively, this suggests that targeting
ERs with antiestrogens limits the growth of existing urothelial carcino-
mas and raises the possibility that this growth-inhibitory potential could
be employed in a chemoprotective manner relative to suppression of
urothelial carcinogenesis in at risk populations and/or prevent bladder
cancer recurrence.
In this report, the chemopreventive efficacy of the selective ER mod-
ulator (SERM) tamoxifen in bladder carcinogenesis was evaluated in a
mouse model of bladder cancer induced with the organ-specific car-
cinogen,N -butyl-N -(4-hydroxybutyl)nitrosamine (BBN). This model
shares morphologic [46], histologic [47,48], and genetic similarities
with higher grades of human bladder cancer [49]. This experiment
demonstrates that tamoxifen administered concurrently with carcino-
gen can significantly reduce the incidence of noninvasive and invasive
bladder cancers in female mice, an effect associated with a reduction in
urothelial proliferation and suppression of ERα expression induced by
exposure to the BBN carcinogen, and suggests that SERMs such as
tamoxifen should be evaluated in clinical trials testing a chemopreven-
tion strategy to limit urothelial carcinogenesis in high-risk populations.
Materials and Methods
Experimental Design
Female C57BL/6/c mice (Charles River Laboratories International,
Inc, Wilmington, MA) were housed under specific pathogen-free
conditions. Animals were divided into six groups (n = 27–30/group;
Figure 1). Group 1 served as the control, which received only tap
water. Group 2 was pretreated with tamoxifen pellets for 3 weeks
before BBN, group 3 had concurrent BBN and tamoxifen treatment
for 12 weeks, group 4 had 12 weeks of BBN followed by tamoxifen
for another 12 weeks, group 5 had concurrent BBN and tamoxifen
followed by 12 weeks additional tamoxifen, while group 6 was treated
with BBN alone. The BBN (TCI America, Portland, OR) carcinogen
was supplied ad libitum at 0.05% in drinking water to mice from 8 to
20 weeks of age. Water consumption was recorded to determine BBN
intake and compared between groups. Tamoxifen treatments (55 μg/day)
were administered by subcutaneous 90-day time-release pellets
(Innovative Research of America, Sarasota, FL) that were implanted be-
tween the scapula. Body weights were measured at multiple time points
between 8 and 32 weeks of age. Animals were monitored for tumor
progression and survival and were killed after 32weeks to obtain bladder
and organ weights. Urinary bladders were processed for subsequent
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histomorphologic and immunohistochemical analyses. To determine if
BBN treatment increased ERα expression in male mice, 20 C57BL/6
male mice were treated with or without BBN (0.05%) in drinking wa-
ter (n = 10/group) from 8 to 20 weeks of age. Animals were killed at 27
weeks; bladders were isolated and split in half with one portion pro-
cessed for histology and immunohistochemistry and the other flash
frozen for RNA isolation. The earlier time point selected for terminat-
ing experiments with male mice is a reflection of the more rapid disease
progression in male than female mice [50] and was selected to proceed
the time point at which bladder obstructions may occur. All animal
procedures were approved by the Institutional Animal Care and Use
Committee of Baylor College of Medicine.
Histopathologic Evaluation and Tissue
Microarray Preparation
To assess bladder histopathology, urinary bladders were first excised,
cut in half longitudinally, and fixed in 10% buffered formalin. Formalin-
fixed bladders were then paraffin embedded, sectioned, and stained
with hematoxylin and eosin following standard protocols. Stained slides
were histopathologically graded by an expert pathologist (S.S.S.), and
bladders were categorized into normal or cancerous, invasive or muscle-
invasive, bladders. These were then reviewed to mark the area for
tumor for the construction of tissue microarrays. Tissue microarrays
were made using 0.6-mm cylindrical cores punched out from the origi-
nal paraffin blocks using a manual tissue arrayer (Beecher Instruments,
Silver Spring, MD). Triplicate cores from individual blocks were made
to enhance the representative reproducibility. Thus, a total of 540 cores
representing 180 female mice were used to generate five master blocks.
Five-micrometer sections were cut from these blocks and placed on
charged slides (Fisher Scientific, Houston, TX) and stained appropri-
ately. Briefly, these slides were deparaffinized, rehydrated, and pretreated
by either microwave or proteinase K for antigen retrieval. Immuno-
histochemical staining was then performed using corresponding anti-
bodies. The staining procedure was based on an indirect biotin-avidin
system with a universal biotinylated Ig secondary antibody, DAB sub-
strate, and hematoxylin counterstain. A negative control slide was
obtained after either omitting the primary antibody or incubating with
an irrelevant antibody (mouse monoclonal Ig).
Tumor Cell Proliferation by Ki-67 Staining
Using the tissue microarrays generated above, sections were also
stained for Ki-67 antigen assessed by immunohistochemistry using
a monoclonal MIB-1 antibody (cloneMIB-1, mouse IgG1, 1:100 from
Dako North America Inc, Carpinteria, CA) that was incubated for
25 minutes in a TechMate 500 Plus (Dako North America Inc) and
visualized with DAB. Images were captured using the Vectra scanner
using the CRI multispectral camera with a ×20 magnification objective
(Caliper, Hopkinton, MA) for the entire tissue section. Image analysis
was done using InForm 1.2 software. InForm was trained to count the
Ki-67–positive cells in representative fields for each tissue section. From
the images, areas of tissue other than urothelia were masked using
Image-Pro Plus software (Media Cybernetics Inc, Bethesda, MD). The
percentage of positively stained cells was calculated using images for the
entire section of tissue.
Apoptosis Assays
Cell death was detected in situ by enzymatic labeling of DNA strand
breaks using terminal deoxynucleotidyl transferase–mediated dUTP
nick end labeling (TUNEL) assays as described previously [51]. For
negative controls, the terminal deoxynucleotidyl transferase was sub-
stituted by deionized water, while sections that were pretreated with
1.0 g/ml DNase I (DN 25; Sigma-Aldrich, St Louis, MO) were used
for the positive controls. Images were captured using Vectra scanner as
described above, and percentage of TUNEL-positive cells was deter-
mined using InForm 1.2 and Image-Pro Plus software.
ER Immunohistochemistry
For immunohistochemical staining of ERα, rabbit polyclonal anti-
bodies against ERα (MC-20; Santa Cruz Biotechnology Inc, Santa
Figure 1. Schematic for evaluation of tamoxifen in a mouse bladder carcinogenesis model. Female C57BL/6 mice were divided into
six groups (n = 27–30 mice/group), and the bladder-specific carcinogen, BBN, was administered to groups 2 to 6 from weeks 8 to 20 in
drinking water, while control mice (group 1) received water alone. Tamoxifen (Tam; 55 μg/day) was administered by slow-release pellets
either before BBN (group 2), concurrent with BBN (group 3), after BBN (group 4), or during and after BBN (group 5). The experiment was
concluded when mice reached 32 weeks of age.
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Cruz, CA) were used. For ERβ, rabbit polyclonal antibody (PAI-310)
was purchased from Affinity BioReagents, Inc (Golden, CO). Assess-
ment of ERα and ERβ expression was performed by a pathologist
(S.S.S.) blinded to the tissue treatment using a modified version
of Allred scoring [52]. The percentage of labeled cells was graded
as follows: 0, no positive cells; 1, 1% to 25% labeled tumor cells;
2, 25% to 50% labeled tumor cells; 3, ≥50% positive tumor cells.
The intensity of peroxidase deposits, ranging from light beige to
dark brown, was scored as 0 (negative), 1 (weak), 2 (moderate), or
3 (strong). A composite score, ranging from 0 to 9, was obtained by
multiplying the percentage grade by the intensity. ER expression
scores were grouped as negative (0), low (<6), and high (≥6).
Analyses of ER mRNA Expression
Bladder specimens obtained from male mice were homogenized
in TRIzol reagent (Invitrogen, Carlsbad, CA) and total RNA was
extracted according to the manufacturer’s recommendations. The
RNA was reverse transcribed using the iScript cDNA Synthesis Kit
(Bio-Rad, Hercules, CA) and the resulting cDNAs were quantitated
by quantitative real-time polymerase chain reaction (qPCR) analyses
using TaqMan or Power SYBR Green Master Mix from Applied
Biosystems (Foster City, CA). Primers and probe for measurement
of mouse ERα (Mm00433149_m1) were purchased as a Taqman
Gene Expression Assay (Applied Biosystems), while primers for mouse
ERβ (forward, 5′-GCAAGATCACTAGAACACACCTTGCC-3′ and
reverse, 5′-AGGACCAGACACCGTAATGATACCC-3′) were pur-
chased from Sigma (St Louis, MO). For normalization, levels of glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH; Mm99999915_g1)
were measured using primers and probe purchased from Applied
Biosystems. Samples were run in a 7500 Fast Real-Time PCR System
(Applied Biosystems) and the mRNA expression was analyzed by the
ΔΔC t method.
Statistical Analysis
Statistical analyses were performed using SAS 9.3 (SAS Institute Inc,
Cary, NC). Wilcoxon Rank-Sum test was used to compare the dif-
ference between groups (pairwise) for bladder weight, Ki-67% posi-
tivity, and TUNEL% positivity since their distributions were highly
skewed. We also performed analysis of variance with log transformation
of the data. These two methods yielded essentially the same results.
Fisher exact test was used to test for an association between treatment
(tamoxifen or BBN treatment) and bladder histopathology, to compare
ERα and ERβ [negative, low (Allred score greater than 0 but <6) or high
(Allred score ≥6)] between different treatment groups, and to test
for an association between histologic classification (normal or tumor)
and expression for ERα (ERα+ and ERα−). A two-sided 0.05 level
was considered statistically significant.
Results
Tamoxifen Conferred Protection against BBN-Induced
Mouse Bladder Carcinogenesis
On the basis of prior work demonstrating the effectiveness of
SERMs in inhibiting the growth of existing urothelial carcinomas
[35,44,45], this study sought to evaluate whether tamoxifen adminis-
tration either before, concurrent with, after, or during and after
carcinogen exposure would impact BBN-induced carcinogenesis in
female mice (Figure 1). On the basis of prior experiments in female
C57BL/6 mice [50,53], carcinogen was administered at 0.05% (vol/
vol) in drinking water to animals aged 8 to 20 weeks, and the study
end point of 32 weeks of age was selected to avoid bladder tumors
progressing to an extent that would cause death. At euthanasia, bladders
were dissected out and drained of urine, and wet weights were obtained;
because of the variation in bladder weights obtained for BBN-treated
mice, data are presented as box-and-whisker plots (Figure 2). The
average wet weights of bladders obtained from animals treated only
with BBN (group 6) were five-fold greater than for the control group
(Wilcoxon Rank-Sum test, P < .0005). Two mice in this group were
killed before the planned study end point of 32 weeks (one at week 31
and a second several days before week 32) due to large bladder tumors;
these animals were included in all subsequent analyses. Mice treated
with tamoxifen either before (weeks 5–8) or after (weeks 20–32)
BBN exposure were also significantly larger than control bladders by
2.5-fold and 1.5-fold, respectively (Wilcoxon Rank-Sum test, P <
.0005). In contrast, the average bladder weights of groups 3 and 5
that received tamoxifen concurrent to (weeks 8–20) or during and
after (weeks 8–32) BBN were not different from control animals;
rather, they were significantly smaller than the bladder weights ob-
tained for mice exposed to BBN alone (Wilcoxon Rank-Sum test, P <
.0005). Body weights were recorded at the end of 32 weeks, but there
were no statistically significant differences between the groups (data
not shown).
Histopathologic evaluation of all the bladders was employed to
determine the effect of tamoxifen on BBN-induced carcinogenesis
and revealed urothelial carcinoma in 76% of the animals treated with
BBN alone; of these 21% had muscle-invasive and 55% had non-
invasive carcinoma (Figure 3). This contrasted significantly from the
control group in which no evidence of bladder cancer, as expected, was
detected. There were fewer (≤7%) cases of muscle-invasive urothelial
Figure 2. Effect of tamoxifen and BBN exposure on bladder
weight. Mice in groups 2 to 5 were given BBN from weeks 8 to
20 and treatedwith tamoxifen for the indicated timeperiods. Bladders
were obtained at 32 weeks and wet weights were determined. Data
are expressed as log transformation of bladder weights (g) using
box-and-whiskers plot. Statistical significances were determined
by Wilcoxon Rank-Sum test.
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carcinoma in mice treated with tamoxifen, regardless of when the SERM
was administered, than in the BBN-only group (21%). Indeed, muscle-
invasive carcinoma was not detected in mice treated with tamoxifen +
BBN concurrently (Fisher exact test, P = .024) and was found at only
low levels in groups treated with tamoxifen after (4%; Fisher exact test,
P = .10) or during and after (3%; Fisher exact test, P = .05) exposure
to BBN.
With respect to non–muscle-invasive carcinoma, 55 μg/day tamoxi-
fen administered concurrently with BBN (weeks 8–20) or during and
after BBN exposure (weeks 8–32) yielded a very low level of disease,
14% and 7%, respectively, resulting in 86% and 90%, respectively,
of the animals having bladders with normal histology (Figure 3). Thus,
these treatment schedules were largely protective against BBN-induced
bladder carcinogenesis. However, a 3-week pretreatment with tamoxi-
fen before BBN exposure or tamoxifen treatment for 12 weeks after
cessation of BBN exposure did not reduce the percentage of animals
with non–muscle-invasive disease in comparison to the BBN-only
group (57% and 63% versus 55% for the BBN-only animals). Overall,
the histopathologic results were consistent with the bladder weight
data (Figure 2) in which the control group was significantly different
from the groups tamoxifen treated pre-BBN (weeks 5–8) or post-
BBN (weeks 20–32) as well as the BBN-alone group (Fisher exact
test, P < .0001). Likewise, groups treated with tamoxifen concurrently
with BBN (weeks 8–20) or during and after BBN (weeks 8–32) were
significantly different from the BBN-only group (Fisher exact test,
P < .0001) but not from the control group. Taken together, these
results indicate that tamoxifen inhibits progression of tumorigenesis
from non–muscle-invasive to muscle-invasive carcinoma regardless of
when tamoxifen is administered. Moreover, tamoxifen treatment con-
currently with BBN exposure inhibits early stages of carcinogenesis
induced by the nitrosamine compound.
Tamoxifen Inhibition of Proliferation in
BBN-Treated Bladder
The proliferative and apoptotic features of the bladder tumors
were evaluated to determine if they were impacted by tamoxifen
treatment. Apoptosis was assessed by TUNEL staining of tissue
microarrays prepared from each of the bladders evaluated for the study.
Quantitative analysis of three cores obtained from each bladder did
not reveal any significant difference in the extent of apoptosis between
the groups (Figure 4A).
Expression of the nuclear antigen Ki-67 was also evaluated by
immunohistochemistry to assess the proliferative rates of the bladders
in the different study groups. Initial assessments revealed significantly
higher percentages of Ki-67–positive cells in each of the BBN-treated
groups, ranging from 0.66% to 4.88% in comparison to the BBN-
naïve group (0.14 ± 0.05%). As the distribution of tumor to normal
histology differed widely between the BBN- and tamoxifen-treated
groups, the average number of proliferating cells for bladders with nor-
mal urothelium was compared to the value obtained for bladder tumors
within the same group. Thus, for mice exposed to BBN alone, the
proliferation index in the tumors was 3.9 times greater than that
determined for bladders with a normal histopathologic evaluation
(Figure 4B). Indeed, comparing normal versus tumor (noninvasive
and muscle invasive) in groups 2 to 6 by two-way analysis of variance
reveals that proliferation of tumor tissues was greater than for the
normal specimens (P < .0001).
Comparisons of proliferation determined for the tumors in each of
the BBN-treated groups revealed high levels of Ki-67–positive cells
in tumor tissues assessed for groups in which tamoxifen was admin-
istered before (weeks 5–8) or after (weeks 20–32) BBN exposure;
this was consistent with the larger bladder weights and greater extent
of tumorigenesis in these groups. In contrast, proliferation for tumors
Figure 3. Effect of tamoxifen and BBN treatment on bladder histopathology. Mice were given BBN with or without the indicated duration
of tamoxifen, and bladder tissues were collected at 32 weeks and processed for histopathologic analyses. Data are expressed as
percentage of animals in each group with urinary bladders graded into normal, non–muscle-invasive, and muscle-invasive tumors.
For statistical significances conducted by Fisher exact test, non–muscle-invasive and muscle-invasive tumors were considered together
in comparison to normal specimens.
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in groups treated during and after (weeks 8–32; Wilcoxon Rank-
Sum test, P < .05) BBN treatment were lower than for the BBN-only
tumors, while the Ki-67 score for those exposed to tamoxifen
concurrently with BBN (weeks 8–20) tended to be lower, but this
did not reach statistical significance (Wilcoxon Rank-Sum test, P =
.082). This was consistent with the protection afforded by these
tamoxifen treatment schedules relative to bladder weight and links
a reduced proliferation index to the reduction in the extent of BBN-
induced tumorigenesis.
Expression of ERs in Bladder Tumors and Normal Urothelium
ERs are the primary mediators of tamoxifen action, and immuno-
histochemical detection of two ER subtypes, ERα and ERβ, was
therefore performed in mouse urinary bladders to examine their
expression in control specimens and to assess the impact of BBN
exposure with or without tamoxifen on their expression. Levels of
ERα and ERβ were assessed by evaluating the percentage of positive
cells and the extent (negative or weak→strong) of staining. A com-
posite score, ranging from 0 to 9, was obtained by multiplying the
percentage grade by the intensity; final ER expression scores were
grouped as negative (0), low (<6), and high (≥6). Prior studies in
rodents and humans indicated that ERβ is the primary ER expressed
in normal urothelium as well as urothelial carcinoma [27,30,35], and
analyses therefore began with immunohistochemistry for ERβ.
The ERβ protein was detected in the superficial and basal layers of
the normal urothelium and was primarily confined to the nucleus,
although some minor staining was also detected in the cytoplasm
(Figure 5A). Stromal, endothelial, and lymphoid cells were largely
negative for ERβ. While each bladder specimen examined, regardless
of whether it was normal or carcinoma, was positive for ERβ stain-
ing, there were modest changes in the distribution (high versus low)
percentages of positive cells noted between the different treatment
Figure 4. Effect of BBN and tamoxifen treatments on apoptosis and proliferation in bladder specimens. Mice were given BBN with or
without tamoxifen for the indicated duration, and bladder tissues were collected for the assessment of (A) apoptosis by TUNEL assay
and (B) cell proliferation by Ki-67 staining. Three punches per animal were arrayed into tissue microarrays for the analysis. For TUNEL,
data are expressed as percent TUNEL-positive cells determined using Image-Pro software. No significant differences were detected
between the groups. For Ki-67 staining, data are expressed as the average ± SEM of percent Ki-67–positive cells for normal or tumor
(noninvasive and muscle-invasive) histology. Statistical significances were determined by Wilcoxon Rank-Sum test.
Translational Oncology Vol. 6, No. 3, 2013 Tamoxifen Chemoprevention of Bladder Cancer George et al. 249
groups. This was not related to a difference in staining between the
invasive carcinoma and noninvasive disease. For the untreated control
group, 79% (23/29) of the animals had high ERβ expression with the
remaining 21% having low ERβ expression (Figure 5B). In the BBN-
only group, ERβ was expressed highly in 89% (24/27) of the speci-
mens, with low expression levels in the remaining 11% of the animals;
this was not significantly different from the control group. For groups
treated with tamoxifen before (weeks 5–8), during (weeks 8–20) or
during and after (weeks 8–32) BBN exposure, fewer animals expressed
high levels of ERβ in comparison to the BBN-only group. This was
not, however, observed for the group treated with tamoxifen after
BBN exposure (weeks 20–32), and thus, no correlation between ERβ
expression and tamoxifen-dependent protection from BBN-induced
carcinogenesis could be detected.
Consistent with prior reports in rodents [24,25], ERα was not
detected in the nucleus or cytoplasm of the urothelium or stroma
of the control bladders (Figure 6A). Surprisingly, however, immuno-
histochemical analyses revealed nuclear ERα immunoreactivity in
the basal urothelia of the urinary bladders of all groups treated with
carcinogen with or without tamoxifen treatment (Fisher exact test,
comparing to control, P < .05). In most positive cases, ERα expression
was low (e.g., weak staining and/or a low percentage of positive cells).
Positive ERα staining was also observed in noninvasive and muscle-
invasive carcinoma. For animals treated with BBN alone, 74% (20/27)
of the bladders revealed either high or low ERα expression (Figure 6B).
A similar percentage of ERα-expressing bladders were also detected
for mice treated with tamoxifen before (weeks 5–8; 68%) and after
(weeks 20–32; 65%) exposure to BBN. Interestingly, ERα expression
was detected in only 39% (Fisher exact test, comparing to BBN-only
group, P < .05) of the animals treated with tamoxifen concurrently with
BBN, and for animals treated with the SERM during and after BBN
exposure (weeks 8–32), the percentage of ERα-positive bladder speci-
mens was reduced (40%; Fisher exact test, comparing to BBN-only
group, P < .05).
Since reduced ERα expression was detected for the tamoxifen treat-
ment groups with the lowest incidence of bladder carcinogenesis, the
distribution of ERα positivity in normal versus tumor specimens was
examined to determine if there was a correlation between ERα expres-
sion and BBN-induced bladder carcinogenesis. Overall, combining all
the histologically normal bladders yields 106 specimens of which only
30% were ERα positive. In contrast, for the combined bladder tumor
specimens from all groups (n = 62), a much higher proportion (76%)
were found to express ERα (Figure 6C) and this was statistically cor-
related by Fisher exact test (P < .001). Taken together, these data
suggest that induction of ERα expression as a consequence of BBN
exposure in this model is associated with bladder carcinogenesis.
To determine if BBN induction of ERα expression was specific
to female mice and thereby potentially contributing to gender differ-
ences in carcinogen-induced bladder cancer [16,50], levels of ERα were
assessed in bladders obtained from male mice treated with BBN from
age 8 to 20 weeks and killed at 27 weeks of age. Similar to our findings
for females, immunohistochemical detection of ERα expression was
Figure 5. Expression of ERβ in bladder specimens obtained from female mice. Mice were given BBN with or without tamoxifen for the
indicated duration, and bladder tissues were collected after 32 weeks for immunohistochemical staining for ERβ. (A) Representative
images of bladder sections obtained from control (group 1), BBN (group 6), and BBN + Tam (group 3) stained for ERβ. (B) Data are
expressed as percentages of animals with IHC scores for ERβ grouped as low (Allred score greater than 0 but <6) or high (Allred score
≥6). Statistical significance was determined by Fisher exact test.
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present only in animals exposed to BBN (Figure 7A). The numbers of
ERα-positive specimens were lower inmales (40%) than for the females
(74%); it is unknown if this is a reflection of the relatively early assess-
ment time point in males (27 weeks) versus females (32 weeks) or a
gender-dependent difference (Figure 7B). The induction of ERα
expression in BBN-treated animals suggested that the carcinogen treat-
ment stimulated expression of the ERα gene. However, the similar
levels of ERα mRNA detected for the control and BBN-treated groups
(Figure 7C ) suggested that the increase in ERα protein detected by
immunohistochemistry was not due to activation of ERα gene expres-
sion but rather reflected an increase in the protein expression through
a post-transcriptional mechanism(s). Not unexpectedly, levels of ERβ
mRNA were similar in control and BBN-treated groups.
Discussion
The ability of the SERMs, raloxifene and tamoxifen, to inhibit prolif-
eration of human bladder cancer cell lines including 5637, RT4, and
TSU-Pr1 in vitro as well as the growth of 5637 xenografts in nude
mice demonstrated the potential of these agents to impede the progres-
sion of existing urothelial carcinoma [35,43–45]. Moreover, knock-
down of ER expression blocks the ability of raloxifene to exert this
inhibitory effect [43]. Recurrence of bladder cancer in patients follow-
ing initial tumor resection is a significant medical problem and the
goal of this study was to employ the BBN-induced urinary bladder
tumor model to determine the ability of tamoxifen to prevent carcino-
genesis in female mice. In our experiments, tamoxifen treatment re-
gardless of when it was administered reduced the extent of invasive
urothelial carcinoma. In addition, tamoxifen when administered con-
currently with carcinogen reduced both invasive and noninvasive dis-
eases and largely protected female mice from urothelial carcinogenesis.
This was reflected in reduced cell proliferation rather than an increase
in apoptosis and is likely mediated by ERβ that is present before and
after BBN treatment in all animals, although the possibility of a contri-
bution from ERα in some carcinogen-treated mice cannot be excluded.
On the basis of the use of tamoxifen for other chemoprevention
purposes (e.g., breast carcinogenesis), our data indicate that tamoxifen
may be a practical approach to limit urothelial carcinogenesis in patient
populations at high risk for bladder tumor recurrence.
BBN induces pathologic alterations in the bladder mucosa beginning
from mucosal dysplasia, papillary or nodular dysplasia, and finally
leading to invasive carcinoma in mice [50,54]. Initiation and promo-
tion of bladder carcinogenesis by BBN is accompanied by increased
cell proliferation in rodents and this is associated with changes in the
expression of genes involved in cell cycle control [49,55–57]. Our data
also indicate an increase in Ki-67–positive cells induced by BBN, and
the reduced proliferation observed for animals treated with tamoxifen
concurrent with BBN is consistent with this SERM’s protective effect.
Although there is little information on tamoxifen effects in normal
urothelium, estrogen treatment has been demonstrated to increase
the proliferation of cultured urothelium cells in vitro [42,58] and over-
expression of aromatase, the enzyme responsible for estradiol produc-
tion, in transgenic mice also leads to increased proliferation in the
urothelial layer [59]. Given the ability of estrogens to increase cell pro-
liferation, it was not unexpected that tamoxifen, which was originally
classified as an antiestrogen, was able to suppress cell proliferation in
Figure 6. Expression of ERα in bladder specimens obtained from female mice. Mice were given BBN with or without tamoxifen for the
indicated duration, and bladder tissues were collected after 32 weeks for immunohistochemical staining for ERβ. (A) Representative
images of bladder sections obtained from control (group 1), BBN (group 6), and BBN + Tam (group 3) stained for ERα. (B) Data are
expressed as percentages of animals with IHC scores for ERα grouped as negative, low (Allred score greater than 0 but <6), or high
(Allred score ≥6). Statistical significance was determined by Fisher exact test; *P < .05 in comparison to all other groups. (C) Distribu-
tion of bladder specimens according to histologic classification (normal or tumor) and expression for ERα.
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normal mouse bladders. Moreover, the ability of tamoxifen and raloxi-
fene to reduce cell proliferation in bladder cancer cells suggests that
SERMs may also limit proliferation after initial carcinogenesis events
[35,43,44,60]. Estrogens may also increase urothelium proliferation
in women as cellular proliferation in the lower urinary tract is also lower
in postmenopausal versus premenopausal women or postmenopausal
women taking hormone replacement [61], suggesting that tamoxifen
may be similarly efficacious in high-risk patients.
Antiestrogens can interfere with growth of different cell systems
through ERα and/or ERβ-dependent pathways and potentially via
impacting other estrogen-regulated pathways that do not rely on
nuclear receptors (e.g., GPR30-regulated proliferation; [62]). How-
ever, in bladder carcinoma cells like RT4 that express both ERs,
either was competent to mediate growth inhibition by raloxifene [43].
In our studies, all the mouse bladder specimens expressed ERβ regard-
less of BBN or tamoxifen treatment, while ERα expression was present
in 74% of the BBN-treated specimens but undetectable in BBN-naïve
bladders. Although this raises the possibility that the protective effect
of tamoxifen may be mediated by ERα and/or ERβ, there are multiple
instances in which tamoxifen provided tumorigenesis protection in
bladders that were ERα negative, suggesting that the protection is
likelymediated by ERβ although the possibility that transient expression
of ERα contributes to the chemoprotective effect of tamoxifen cannot
be excluded.
While the available data do not indicate that ERα is obligatory for
the protective effect of tamoxifen in this carcinogen-induced model,
its expression in the majority of bladders obtained from BBN-treated
animals and the absence of any detectable ERα staining in bladders
from BBN-naïve animals raises the possibility that the induction of
ERα expression following carcinogen exposure may contribute to
tumorigenesis. Prior studies failed to detect ERα as a key player in
BBN-induced bladder carcinogenesis in mice or rats [56,57,63];
instead, they identified pathways such as those involving epidermal
growth factor receptor–Ras, cell cycle, transforming growth factor–β,
c-Myc, apoptosis, and integrin-mediated cell adhesion in BBN-induced
carcinogenesis. However, in a very different model of bladder cancer
in which female mice are exposed to inorganic arsenic in utero fol-
lowed by postnatal diethylstilbestrol, the resulting bladder transitional
cell carcinomas are positive for ERα [64], raising the possibility that
expression of this receptor may contribute to a cancer phenotype.
The role of ERα as a positive regulator of proliferation and its asso-
ciation with inflammatory responses and the development of malig-
nancy are well established [41]. Nonetheless, the importance of ERα
to urothelial cancer in humans is unclear with most studies report-
ing little expression of the receptor, although a recent report linked a
loss of ERα expression with higher grade tumors [20,32–36,38,65].
Future studies with BBN exposure of mice with a urothelial-specific
knockout of ERα should be able to address potential roles of ERα in
carcinogen-induced tumorigenesis.
The absence of ERα expression in BBN-naïve bladder urothelium
of females is consistent with a prior report in which immunohisto-
chemical staining for ERα in female mouse urinary bladder and urethra
was negative [24]. Our finding of BBN induction of ERα protein
expression in the urothelium of female and male mice indicates that
this response is not gender-specific and raises the possibility of a con-
tribution of ERα to BBN-induced carcinogenesis in male mice. The ap-
pearance of ERα protein detected by immunohistochemistry (IHC) was
not reflected at the mRNA level, indicating that the induction of this
receptor’s expression is likely mediated through a post-transcriptional
event rather than a significant increase in ERα gene expression. This
would also explain why prior gene profiling studies did not detect an
increase in ERα in this model [56,57,63]. There are multiple potential
mechanisms by which ERα expression in the urothelium of BBN-
treated mice may be increased following BBN exposure. Several micro-
RNAs are known to target ERα in cell lines and tissues [66] and a
reduction in their expression would be expected to increase the receptor’s
expression. Interestingly, expression of let-7c, a member of the let-7
microRNAs that target ERα [67], is decreased in bladder tumors arising
in BBN-treated rats and postulated to play a significant role in onco-
genesis [68]. Conversely, stabilization of ERα protein, potentially from
a reduction in ubiquitin ligases (e.g., Mdm2) that target the receptor for
degradation by the proteasome [69], could also contribute to increased
protein expression in urothelium following carcinogen exposure.
The expression of ERβ in mice from all the treatment groups, even
in the absence of ERα, raises the possibility that the former receptor
mediates the chemoprotective effects of tamoxifen. ERβ is largely con-
sidered to be antiproliferative and proapoptotic, thereby exerting bene-
ficial effects in multiple different cancers [41]. Although not fully
elucidated, possible mechanisms for tumor suppression by ERβ include
inducing G1 arrest of the cell cycle by regulating cell cycle checkpoint
genes [70], impeding G2/M progression by inhibiting CDK1 activity
[71] and suppressing inflammatory pathways [72]. In addition, where
ERα and ERβ are co-expressed, the latter may block ERα-mediated
Figure 7. Expression of ERs in bladder obtained from male mice.
Mice were given drinking water only (control) or water containing
0.05%BBN fromweeks 8 to 20, and urinary bladders were collected
at 27weeks for analysis of ER expression. (A) Immunohistochemical
staining and (B) quantitative IHC results for ERα expression deter-
mined for male mouse bladder specimens. (C) Levels of mRNA ex-
pression for ERα (left panel) and ERβ (right panel) were determined
by reverse transcription–qPCR. Values represent n = 10 per group
and are presented as the average ± SEM.
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events such as estrogen-dependent cell proliferation [73]. Collectively,
this may be the result of distinct profiles of genes regulated by ERα
versus ERβ [74], but it could also reflect a direct effect of ERβ on
ERα activity, potentially through formation of ERα/ERβ heterodimers.
Indeed, ERβ can disrupt ERα recruitment to estrogen response ele-
ments and block ERα-dependent recruitment of other factors required
for optimal gene expression [75]. There is also evidence that ERβ can
reduce ERα expression [75,76].
In general, tamoxifen appears to reduce the extent of invasive carci-
noma in this carcinogen-induced mouse model and this bodes well
for the use of tamoxifen in human chemoprevention trials where in-
hibition of the formation of invasive cancer is of primary concern. This
would be of significant benefit to many patients who initially present
with non–muscle-invasive disease that must undergo long-term moni-
toring for future development of invasive carcinoma. The reduction
in invasive disease achieved by concurrent BBN and tamoxifen ad-
ministration is not surprising, as the reduction in noninvasive cancer
indicates that this tamoxifen treatment scheme inhibits early stages of
carcinogenesis. However, administration either before or after BBN
exposure reduced the extent of invasive carcinoma without influencing
levels of noninvasive disease, suggesting that tamoxifen administered
independently of carcinogen can inhibit later stages of carcinogenesis.
In support of this, in other experiments in which we have evaluated
BBN-treated mice by micro-ultrasound, dysplasia of the urothelium
is evident during the latter third of the BBN exposure period (e.g.,
weeks 16–20; George & Smith, unpublished observations) consistent
with prior findings [50]. Thus, SERM treatment begun after the cessa-
tion of BBN administration appears to be able to limit the progression
from non–muscle-invasive to muscle-invasive carcinoma. While the
receptor responsible for this apparent inhibition of invasion by tamoxi-
fen is unknown in the BBN carcinogenesis model, it is interesting to
note that ERβ is associated with a block in epithelial-to-mesenchymal
transition in mammary and prostate cancer [77,78] and stimulation
of bladder cancer cell lines with the ERβ-selective ligand diarylpro-
pionitrile induces expression of E-cadherin while reducing N-cadherin
expression [40].
In addition, administration of tamoxifen concurrently with BBN
exposure reduced invasive as well as noninvasive carcinoma, suggesting
an effect of concurrent tamoxifen treatment in preventing early stages
of carcinogenesis. Whether this is due to a direct protective effect on
the urothelium or an indirect effect, potentially through regulation of
BBN metabolism, is unknown at the present time. The carcinogen
BBN is subject to two possible metabolic fates. In the first one, BBN
is metabolized to N -nitrosobutyl(3-carboxypropyl)amine and this
product exerts carcinogenic effects on urothelial cells [79,80]. Alterna-
tively, BBN is a substrate for several phase II drug metabolism enzymes,
such as the UDP-glucuronosyltransferases (UGTs) that catalyze the
glucuronidation of carcinogens making them water soluble for excre-
tion [81]. A recent report indicates that estradiol can induce expression
of the detoxifying enzyme UGT1a in immortalized SVHUC urothelial
cells while reducing expression in 5637, UMUC3, and J82 bladder
cancer cell lines [82], raising the possibility of ER-dependent chemo-
protection through metabolism of BBN. Indeed, estrogen stimulation
of UGT1a has been postulated to play a role in the lower incidence
of bladder cancer in females versus males [82]. Tamoxifen alone was
unable to alter UGT1a mRNA expression in these studies, and tamoxi-
fen inhibition of endogenous estrogens would be anticipated to reduce
UGT1a expression, thereby exacerbating BBN-induced carcinogenesis.
The reduction in carcinogenesis achieved by tamoxifen in the present
study suggests that the protection conferred by this SERM is indepen-
dent of UGT1a, although a potential contribution from alterations in
other metabolic pathways cannot be ruled out at the present time.
Tamoxifen has a long history of use for treatment of breast cancer
and, more recently, chemoprevention in women at high risk of devel-
oping this disease. Tamoxifen has also been employed in the treatment
of other cancers including ovarian, hepatocellular carcinoma and malig-
nant glioma [83]. Relative to bladder cancer, tamoxifen has been shown
to enhance the sensitivity of human transitional carcinoma cells to
standard chemotherapeutic drugs such as doxorubicin and cisplatin
in in vitro studies [84,85]. Tamoxifen has also been evaluated for
advanced stage bladder cancer patients in combination with cisplatin-
based therapy. Although there was no chemotherapy only arm in this
small study, the addition of tamoxifen was well tolerated and the combi-
nation therapy achieved responses comparable to historical controls [86].
A case report also describes the complete remission of a male patient with
metastatic transitional cell carcinoma (TCC) given tamoxifen to treat
gynecomastia [87]. These prior studies suggest a potential role for tamox-
ifen in treatment of existing bladder cancer, while our study addresses a
chemoprevention application of this SERM in a well-established animal
model with applicability to human disease. This may be useful in patients
who are at high risk for recurrence following initial tumor resection with
or without subsequent immunotherapy and is supported by the high
incidence of ERβ expression in normal urothelium as well as urothelial
tumors of bladder cancer patients. Decipheringmolecular targets through
which the protective effects of tamoxifen are achieved may ultimately
allow for selection of patients that would benefit from an SERM-based
strategy for chemoprevention of bladder cancer.
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